

Early Stage BTK Assets

DRUG	DRUG CLASS	FIRM	DISEASE	DEVELOPMENT STAGE
NX-5948	BTK DEGRADER	Nurix	CLL, NHL, Waldenström macroglobulinemia	Phase 1b/2
UBX-303-1	BTK DEGRADER	Ubix Therapeutics	R/R B-cell malignancies	Phase 1
AC0676	BTK DEGRADER	Accutar Biotech	R/R B-cell malignancies	Phase 1
NX-2127	BTK + IKZF DUAL DEGRADER	Nurix	NHL	Phase 1a
BGB-16673	BTK-TARGETED CDAC	BeOne Medicines	R/R MCL, R/R CLL	Phase 2
LP-168	BTK INHIBITOR	Newave Pharma	R/R B-cell malignancies	Phase 1a/1b
ABBV-101	BTK INHIBITOR	AbbVie	Hematologic Tumors	Phase 1
DTRMWXHS-12	BTK INHIBITOR	Zhejiang DTRM Biopharma	R/R lymphomas	Phase 1
JNJ-64264681	BTK INHIBITOR	Johnson and Johnson	B-cell malignancies	Phase 1
TT-01488	BTK INHIBITOR	TransThera Sciences	R/R B-cell malignancies	Phase 1

View All Results →